Imatinib Axios

Imatinib, the active ingredient in Imatinib Axios, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It targets specific cellular enzymes that drive malignant growth and is approved for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients, helping to control disease progression.

GNH USA supplies Imatinib Axios as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib acts on BCR‑ABL and related kinases, providing targeted therapy for hematologic and solid tumours. - Chronic Myeloid Leukemia (CML): achieves disease control by reducing leukemic cell proliferation. - Gastrointestinal Stromal Tumor (GIST): achieves tumor shrinkage and disease stabilization. - Other BCR‑ABL positive malignancies: provides targeted inhibition of disease‑driving kinase activity.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the lower limbs. - Muscle cramps: painful involuntary contractions. - Fatigue: generalized lack of energy. - Diarrhea: loose stools, sometimes watery. - Rash: skin irritation or erythema.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe neutropenia: marked reduction in white blood cells. - Cardiac failure: reduced heart function, especially in patients with pre‑existing disease. - Pulmonary hypertension: increased pressure in lung arteries. - Severe allergic reactions: anaphylaxis or Stevens‑Johnson syndrome. - Tumor lysis syndrome: rapid tumour cell breakdown causing metabolic disturbances.

Before initiating therapy, clinicians should evaluate baseline health status and monitor patients regularly. - Monitor blood counts: check complete blood count frequently to detect cytopenias. - Assess liver function: perform hepatic enzyme tests before and during treatment. - Evaluate cardiac status: consider echocardiogram in patients with cardiac risk factors. - Avoid in known hypersensitivity: discontinue if severe allergic reaction occurs. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib may interact with several medicines, requiring dose adjustments or monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can markedly increase imatinib exposure. - Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels. - Concomitant use with antacids containing aluminum or magnesium: may impair absorption.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Diuretics (e.g., furosemide): can increase risk of fluid retention. - QT‑prolonging agents (e.g., quinidine): may raise the chance of cardiac arrhythmias.